A randomized, open-label, crossover study of once monthly oral Bonviva [ibandronic acid] compared with alendronate [alendronic acid] to determine patient preference in women with post-menopausal osteoporosis
Phase of Trial: Phase IV
Latest Information Update: 23 Feb 2010
At a glance
- Drugs Alendronic acid; Ibandronic acid
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Roche
- 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
- 20 Jun 2006 New trial record.